» Articles » PMID: 37988981

ABCC4 Impacts Megakaryopoiesis and Protects Megakaryocytes Against 6-mercaptopurine Induced Cytotoxicity

Overview
Date 2023 Nov 21
PMID 37988981
Authors
Affiliations
Soon will be listed here.
Abstract

The role of ABCC4, an ATP-binding cassette transporter, in the process of platelet formation, megakaryopoiesis, is unknown. Here, we show that ABCC4 is highly expressed in megakaryocytes (MKs). Mining of public genomic data (ATAC-seq and genome wide chromatin interactions, Hi-C) revealed that key megakaryopoiesis transcription factors (TFs) interacted with ABCC4 regulatory elements and likely accounted for high ABCC4 expression in MKs. Importantly these genomic interactions for ABCC4 ranked higher than for genes with known roles in megakaryopoiesis suggesting a role for ABCC4 in megakaryopoiesis. We then demonstrate that ABCC4 is required for optimal platelet formation as in vitro differentiation of fetal liver derived MKs from Abcc4 mice exhibited impaired proplatelet formation and polyploidization, features required for optimal megakaryopoiesis. Likewise, a human megakaryoblastic cell line, MEG-01 showed that acute ABCC4 inhibition markedly suppressed key processes in megakaryopoiesis and that these effects were related to reduced cAMP export and enhanced dissociation of a negative regulator of megakaryopoiesis, protein kinase A (PKA) from ABCC4. PKA activity concomitantly increased after ABCC4 inhibition which was coupled with significantly reduced GATA-1 expression, a TF needed for optimal megakaryopoiesis. Further, ABCC4 protected MKs from 6-mercaptopurine (6-MP) as Abcc4 mice show a profound reduction in MKs after 6-MP treatment. In total, our studies show that ABCC4 not only protects the MKs but is also required for maximal platelet production from MKs, suggesting modulation of ABCC4 function might be a potential therapeutic strategy to regulate platelet production.

References
1.
Vijey P, Posorske B, Machlus K . In vitro culture of murine megakaryocytes from fetal liver-derived hematopoietic stem cells. Platelets. 2018; 29(6):583-588. PMC: 6323647. DOI: 10.1080/09537104.2018.1492107. View

2.
Tomer A, Friese P, Conklin R, Bales W, Archer L, Harker L . Flow cytometric analysis of megakaryocytes from patients with abnormal platelet counts. Blood. 1989; 74(2):594-601. View

3.
Corces M, Buenrostro J, Wu B, Greenside P, Chan S, Koenig J . Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nat Genet. 2016; 48(10):1193-203. PMC: 5042844. DOI: 10.1038/ng.3646. View

4.
Nofer J, Herminghaus G, Brodde M, Morgenstern E, Rust S, Engel T . Impaired platelet activation in familial high density lipoprotein deficiency (Tangier disease). J Biol Chem. 2004; 279(32):34032-7. DOI: 10.1074/jbc.M405174200. View

5.
Ogura M, Morishima Y, Ohno R, Kato Y, Hirabayashi N, Nagura H . Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood. 1985; 66(6):1384-92. View